DermBiont develops targeted small molecule therapeutics and biotherapeutics to treat skin diseases by addressing the underlying causes, such as microbiome imbalances. Their pipeline includes treatments for conditions like seborrheic keratosis, hyperpigmentation, atopic dermatitis, tinea pedis, and onychomycosis.
Funding
$86.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DPFounders
Product
Problem
Many skin diseases are caused by microbiome imbalances or other underlying factors that are not addressed by traditional treatments. Current topical treatments may not effectively target the root causes of these conditions, leading to limited efficacy and potential recurrence. This is particularly true for conditions like seborrheic keratosis, hyperpigmentation, atopic dermatitis, tinea pedis, and onychomycosis.
Solution
DermBiont is a precision dermatology company developing targeted topical therapeutics and biotherapeutics designed to treat, cure, and prevent skin diseases by addressing their underlying causes. The company's approach involves developing small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair imbalances in the skin microbiome. Their pipeline includes treatments for a range of dermatological conditions, focusing on delivering targeted therapies directly to the affected areas. By focusing on the root causes of skin diseases, DermBiont aims to provide more effective and long-lasting solutions compared to traditional treatments. The company is advancing topical therapeutics in rare disease oncology and aesthetic dermatology.
Target Audience
DermBiont's primary target audience includes patients suffering from skin diseases such as seborrheic keratosis, hyperpigmentation, atopic dermatitis, tinea pedis, and onychomycosis, as well as dermatologists and other healthcare professionals treating these conditions.
Features
- Development of targeted small molecule therapeutics with specific mechanisms of action.
- Biotherapeutics designed to restore balance to the skin microbiome.
- Pipeline includes SM-020 for seborrheic keratosis, demonstrating positive Phase 2a data for basal cell carcinoma.
- SM-030 for hyperpigmentation disorders of the skin.
- DBI-001 & DBI-002 for atopic dermatitis, tinea pedis, and onychomycosis.
- Focus on topical delivery for targeted treatment of skin conditions.